Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer

In the last few years the advent of targeted therapies against oncogenic drivers significantly improved the survival of non small cell lung cancer (NSCLC) patients with a favourable toxicity profile. Therefore, genetic testing, including at least EGFR mutations and ALK/ROS1 rearrangements, should be...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Front Oncol
Главные авторы: Tartarone, Alfredo, Lapadula, Vittoria, Di Micco, Concetta, Rossi, Gemma, Ottanelli, Carlotta, Marini, Andrea, Giorgione, Roberta, Ferrari, Katia, Catalano, Martina, Voltolini, Luca, Mini, Enrico, Roviello, Giandomenico
Формат: Artigo
Язык:Inglês
Опубликовано: Frontiers Media S.A. 2021
Предметы:
Oncology
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176852/
https://ncbi.nlm.nih.gov/pubmed/34094913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.632256
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы